相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis
Hiroyuki Okumura et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2020)
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
C. A. Gentry et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Toxigenic Clostridium difficile carriage in general practice: results of a laboratory-based cohort study
F. Barbut et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
Christian Lodberg Hvas et al.
GASTROENTEROLOGY (2019)
Effect of using fidaxomicin on recurrent Clostridium difficile infection
M. Biggs et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Update of treatment algorithms for Clostridium difficile infection
R. E. Ooijevaar et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
How to: Surveillance of Clostridium difficile infections
M. Krutova et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan
Hiroshige Mikamo et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis
Tumas Beinortas et al.
LANCET INFECTIOUS DISEASES (2018)
Economic burden and cost-effective management of Clostridium difficile infections
S. M. Heimann et al.
MEDECINE ET MALADIES INFECTIEUSES (2018)
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
Hannah E. Burton et al.
PHARMACOECONOMICS (2017)
Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation
Kelly R. Reveles et al.
PHARMACOTHERAPY (2017)
Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France
Maureen Watt et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations
S. D. Goldenberg et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)
Clostridium difficile ribotype 176-A predictor for high mortality and risk of nosocomial spread?
Sylvia Polivkova et al.
ANAEROBE (2016)
Enhanced surveillance of Clostridium difficile infection occurring outside hospital, England, 2011 to 2013
W. N. Fawley et al.
EUROSURVEILLANCE (2016)
Clostridium difficile infection
Wiep Klaas Smits et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
Jason C. Gallagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2014)
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
S. B. Debast et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison
Oliver A. Cornely et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy
Mark A. Miller et al.
BMC INFECTIOUS DISEASES (2013)
Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
Anilrudh A. Venugopal et al.
CLINICAL INFECTIOUS DISEASES (2012)
Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
Karl Weiss et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
Irina Artsimovitch et al.
CLINICAL INFECTIOUS DISEASES (2012)
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Oliver A. Comely et al.
CLINICAL INFECTIOUS DISEASES (2012)
Can we identify patients at high risk of recurrent Clostridium difficile infection?
C. P. Kelly
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection
P. N. Wiegand et al.
JOURNAL OF HOSPITAL INFECTION (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
M. P. Bauer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
分享论文
